FOLFOX-6 PLUS IMATINIB, BEVACIZUMAB AND CETUXIMAB IN ADVANCED UNTREATED COLORECTAL CANCER

被引：0
|
作者：
Andretta, V [1 ]
Bennicelli, E. [1 ]
Pessino, A. [1 ]
Caprioni, F. [1 ]
Decian, F. [1 ]
Di Benedetto, M. [1 ]
Sobrero, A. [1 ]
机构：
[1] Azienda Osped Univ San Martino Genova, Genoa, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：113 / 113
页数：1
相关论文
共 50 条
  • [31] FOLFOXIRI Plus Bevacizumab Versus FOLFOX/FOLFIRI Plus Bevacizumab for Metastatic Colorectal Cancer: An Updated Meta-Analysis
    Muhibullah, Fnu
    Shafique, Nouman
    Khakwani, Anum
    Qadeer, Abdul
    Bajwa, Shammas Farooq
    Ehsan, Amna
    Aiman, Wajeeha
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S175 - S176
  • [32] Cetuximab or bevacizumab in metastatic colorectal cancer?
    Sclafani, Francesco
    Cunningham, David
    LANCET ONCOLOGY, 2014, 15 (10): : 1040 - 1041
  • [33] Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report
    Malavasi, Norma
    Ponti, Giovanni
    Depenni, Roberta
    Bertolini, Federica
    Zironi, Sandra
    Luppi, Gabriele
    Conte, Pier Franco
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2009, 2
  • [34] Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report
    Norma Malavasi
    Giovanni Ponti
    Roberta Depenni
    Federica Bertolini
    Sandra Zironi
    Gabriele Luppi
    Pier Franco Conte
    Journal of Hematology & Oncology, 2
  • [35] Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer
    Hori, Natsuko
    Iwasa, Satoru
    Hashimoto, Hironobu
    Yanai, Takako
    Kato, Ken
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Murakoshi, Kouji
    Yokote, Nobuaki
    Yamamoto, Hiroshi
    Shimada, Yasuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (03) : 435 - 438
  • [36] Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer
    Natsuko Hori
    Satoru Iwasa
    Hironobu Hashimoto
    Takako Yanai
    Ken Kato
    Tetsuya Hamaguchi
    Yasuhide Yamada
    Kouji Murakoshi
    Nobuaki Yokote
    Hiroshi Yamamoto
    Yasuhiro Shimada
    International Journal of Clinical Oncology, 2013, 18 : 435 - 438
  • [37] FOLFOX/Bevacizumab plus /- Irinotecan in advanced colorectal cancer (AIO) "CHARTA": Final results and multivariate prognostic factor analysis
    Hans-Joachim, Schmoll
    Benjamin, Garlipp
    Christian, Junghanss
    Malte, Leithaeuser
    Arndt, Vogel
    Michael, Schaefers
    Ulrich, Kaiser
    Heinz-Gert, Hoeffkes
    Axel, Florschuetz
    Joern, Ruessel
    Stephan, Kanzler
    Thomas, Edelmann
    Helmut, Forstbauer
    Thomas, Goehler
    Carla, Hannig
    Bert, Hildebrandt
    Joerg, Steighardt
    Franziska, Cygon
    Fabian, Meinert
    Alexander, Stein
    ANNALS OF ONCOLOGY, 2017, 28
  • [38] FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer
    Ghosn, Marwan
    Farhat, Fadi
    Kattan, Joseph
    Younes, Fariha
    Moukadem, Walid
    Nasr, Fadi
    Chahine, Georges
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (01): : 15 - 20
  • [39] Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)
    Suenaga, Mitsukuni
    Fujimoto, Yoshiya
    Matsusaka, Satoshi
    Shinozaki, Eiji
    Akiyoshi, Takashi
    Nagayama, Satoshi
    Fukunaga, Yosuke
    Oya, Masatoshi
    Ueno, Masashi
    Mizunuma, Nobuyuki
    Yamaguchi, Toshiharu
    ONCOTARGETS AND THERAPY, 2015, 8 : 1111 - 1118
  • [40] A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer
    Michael, M.
    Zalcberg, J.
    Gibbs, P.
    Lipton, L.
    Gouillou, M.
    Jefford, M.
    McArthur, G.
    Copeman, M.
    Lynch, K.
    Tebbutt, N. C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 321 - 330
12345